WASHINGTON _ Medicine for the most severe respiratory symptoms caused by the coronavirus could clear clinical trials as soon as this summer, its manufacturer said on Monday, after receiving approval to test the drug from the Food and Drug Administration.
The FDA hopes that Actemra, which is already approved for use in the United States against rheumatoid arthritis, may also be able to relieve similar inflammations experienced by severely ill coronavirus patients who have pneumonia.
China listed Actemra in its treatment guidelines for patients severely ill from COVID-19, the disease caused by the coronavirus, in early March.
